Pain RSS Page 12

Filtered By:
Vaccination: Influenza Vaccine

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 427 results found since Jan 2013.

A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system
CONCLUSION: MAS-1 adjuvant in a 0.3 mL dose volume provided HA dose-sparing effects without safety concerns and induced higher HAI antibody and seroconversion responses through at least 6 months, demonstrating potential to provide greater vaccine efficacy throughout an influenza season in younger adults. In summary, MAS-1 may provide enhanced, more durable and broader protective immunity compared with non-adjuvanted SD IIV. Clinical Trial Registry: ClinicalTrials.gov # NCT02500680.PMID:35125219 | DOI:10.1016/j.vaccine.2022.01.034
Source: Vaccine - February 7, 2022 Category: Allergy & Immunology Authors: Geoffrey J Gorse Stephen Grimes Helen Buck Hussain Mulla Peter White Heather Hill Jeanine May Sharon E Frey Peter Blackburn Source Type: research

MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly
CONCLUSION: MAS-1 adjuvant provided HA dose-sparing without safety concerns at the 0.3 mL dose, but the 0.5 mL dose caused late injection site reactions. MAS-1-adjuvanted IIV induced higher HAI antibody responses with prolonged durability including against historical strains, thereby providing greater potential vaccine efficacy in the elderly throughout an influenza season. Clinical Trial Registry: ClinicalTrials.gov # NCT02500680.PMID:35125224 | DOI:10.1016/j.vaccine.2022.01.035
Source: Vaccine - February 7, 2022 Category: Allergy & Immunology Authors: Geoffrey J Gorse Stephen Grimes Helen Buck Hussain Mulla Peter White Heather Hill Jeanine May Sharon E Frey Peter Blackburn Source Type: research

Repurposing potential of rimantadine hydrochloride and development of a promising platinum(II)-rimantadine metallodrug for the treatment of Chikungunya virus infection
Acta Trop. 2021 Dec 31;227:106300. doi: 10.1016/j.actatropica.2021.106300. Online ahead of print.ABSTRACTMost of the patients infected with Chikungunya virus (CHIKV) develop chronic manifestations characterized by pain and deformity in joints, impacting their quality of life. The aminoadamantanes, in their turn, have been exploited due to their biological activities, with amantadine and memantine recently described with anti-CHIKV activities. Here we evaluated the antiviral activity of rimantadine hydrochloride (rtdH), a well-known antiviral agent against influenza A, its platinum complex (Pt-rtd), and the precursor cis-[P...
Source: Acta Tropica - January 3, 2022 Category: Infectious Diseases Authors: Igor Andrade Santos Anna Karla Dos Santos Pereira Marco Guevara-Vega Raphael Enoque Ferraz de Paiva Robinson Sabino-Silva Fernando R G Bergamini Pedro P Corbi Ana Carolina G Jardim Source Type: research

Brand-Specific Enhanced Safety Surveillance Study of GSK ’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season
ConclusionThis ESS study assessed AEs in near real time. The COVID-19 pandemic did not alter the safety profile of GSK ’s IIV4. No safety signals were detected during the study, which confirms the excellent safety profile of GSK’s IIV4.
Source: Infectious Diseases and Therapy - December 27, 2021 Category: Infectious Diseases Source Type: research

Consumer Health: Understanding the flu and why you need to get a flu shot
National Influenza Vaccination Week will be observed Dec. 5 –11, which makes this a good time to learn more about the flu and why you need to get a flu shot. What many people call the flu is actually viral gastroenteritis, or stomach flu, which is characterized by diarrhea, nausea, and abdominal cramps and pain. Influenza is the true flu. It's a viral infection that attacks your respiratory system, including your nose, throat and lungs. At first, flu…
Source: News from Mayo Clinic - December 8, 2021 Category: Databases & Libraries Source Type: news

Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting
TITUSVILLE, N.J. – October 14, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.Data presentations from eight abstracts will provide additional evidence supporting the role of objective multiparameter risk assessment approaches in helping to optimize treatment and care for pulmonary arterial hypertension (PAH), as well as the impact of earlier and comprehensive therapy with UPTRAVI�...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Staying Safe From Sepsis
This post was adapted with permission from the NIH News in Health article, “Staying Safe From Sepsis.” Your immune system is on patrol every day. It protects your body from bacteria, viruses, and other germs. But if something goes wrong, it can also cause big problems. White blood cells undergoing a cascade of biochemical changes that is part of the immune response. Credit: Xiaolei Su, HHMI Whitman Center of the Marine Biological Laboratory. Sepsis happens when your body’s response to an infection spirals out of control. Your body releases molecules into the blood called cytokines to fight the infecti...
Source: Biomedical Beat Blog - National Institute of General Medical Sciences - September 15, 2021 Category: Research Authors: Chrissa Chverchko Tags: Injury and Illness Infectious Diseases Sepsis Source Type: blogs

Safety and Impact on Training of the Influenza Vaccines in Elite Athletes Participating in the Rio 2016 Olympics
Conclusions: Athletes tolerated influenza immunization well. If they are going to travel to the other hemisphere during the influenza season, the use of the second influenza vaccine should be advised. Athletes should anticipate modification of trainings for 2 days after vaccination.
Source: Clinical Journal of Sport Medicine - September 1, 2021 Category: Sports Medicine Tags: Original Research Source Type: research

Fight Aging! Newsletter, August 30th 2021
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out mo...
Source: Fight Aging! - August 29, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

IJERPH, Vol. 18, Pages 8995: COVID-19 Screening by Anti-SARS-CoV-2 Antibody Seropositivity: Clinical and Epidemiological Characteristics, Comorbidities, and Food Intake Quality
In conclusion, this study supports the association of diabetes as a principal risk factor for SARS-CoV-2 infection in the Mexican population. The results do not support previous associations between blood group or influenza vaccination as protective factors against SARS-CoV-2 infection. However, frequent consumption of polyunsaturated fats is highlighted as a new possible associated factor with COVID-19, which more studies should corroborate as with all novel findings.
Source: International Journal of Environmental Research and Public Health - August 26, 2021 Category: Environmental Health Authors: Gabriela Macedo-Ojeda Jos é Francisco Muñoz-Valle Patricia Yokogawa-Teraoka Andrea Carolina Machado-Sulbar án Mar ía Guadalupe Loza-Rojas Atziri Citlally Garc ía-Arredondo Rafael Tejeda-Constantini Alejandra Natali Vega-Maga ña Guillermo Gonz ález- Tags: Article Source Type: research

Vaccine associated myocarditis revisited with COVID-19 mRNA vaccines
When I had reviewed the topic of vaccine associated myocarditis for an editorial in the BMH Medical Journal in 2017, most of the cases were associated with small pox vaccination [1]. There were also reports of streptococcal pneumonia vaccine and influenza vaccine associated myocarditis. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) used in the vaccine were also implicated in some cases [2,3]. While the large scale vaccination for small pox in an attempt to prepare for potential bioterrorism was the association in 2003 [4], COVID-19 mRNA vaccines are currently in the limelight for vaccine induced myocarditis...
Source: Cardiophile MD - July 22, 2021 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology Source Type: blogs

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20